Beginning in July 2016, Merck will experience a supply disruption to the syringe presentation of GARDASIL® 9, pediatric formulations of RECOMBIVAX® HB and VAQTA® as well as adult formulation of RECOMBIVAX® HB. Please note that only the syringes have been affected and the suppy disruption does not include vial formulations. Merck anticipates that supplies of the syringes will be depleted until the second quarter of 2017.